172 related articles for article (PubMed ID: 12646281)
21. 5-HT2C receptor activation prevents stress-induced enhancement of brain 5-HT turnover and extracellular levels in the mouse brain: modulation by chronic paroxetine treatment.
Mongeau R; Martin CB; Chevarin C; Maldonado R; Hamon M; Robledo P; Lanfumey L
J Neurochem; 2010 Oct; 115(2):438-49. PubMed ID: 20796171
[TBL] [Abstract][Full Text] [Related]
22. Age modulates the long-term but not the acute effects of the serotonergic neurotoxicant 3,4-methylenedioxymethamphetamine.
Broening HW; Bacon L; Slikker W
J Pharmacol Exp Ther; 1994 Oct; 271(1):285-93. PubMed ID: 7965726
[TBL] [Abstract][Full Text] [Related]
23. The effects of MDMA pretreatment on the behavioural effects of other drugs of abuse in the rat elevated plus-maze test.
Sumnall HR; O'Shea E; Marsden CA; Cole JC
Pharmacol Biochem Behav; 2004 Apr; 77(4):805-14. PubMed ID: 15099927
[TBL] [Abstract][Full Text] [Related]
24. 1-(1-naphthyl)-piperazine, a mixed 5-HT1A and 5-HT2A/2C receptor ligand, elicits an anxiolytic-like effect in the open-field test without changes in 5-HT metabolism.
Pruus K; Rudisaar R; Vaarmann A; Matto V; Allikmets L
Methods Find Exp Clin Pharmacol; 2002 Apr; 24(3):151-7. PubMed ID: 12087877
[TBL] [Abstract][Full Text] [Related]
25. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.
Sanchez V; Camarero J; Esteban B; Peter MJ; Green AR; Colado MI
Br J Pharmacol; 2001 Sep; 134(1):46-57. PubMed ID: 11522596
[TBL] [Abstract][Full Text] [Related]
26. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.
Battaglia G; Yeh SY; O'Hearn E; Molliver ME; Kuhar MJ; De Souza EB
J Pharmacol Exp Ther; 1987 Sep; 242(3):911-6. PubMed ID: 2443644
[TBL] [Abstract][Full Text] [Related]
27. Ethanol, 3,4-methylenedioxymethamphetamine (ecstasy) and their combination: long-term behavioral, neurochemical and neuropharmacological effects in the rat.
Cassel JC; Riegert C; Rutz S; Koenig J; Rothmaier K; Cosquer B; Lazarus C; Birthelmer A; Jeltsch H; Jones BC; Jackisch R
Neuropsychopharmacology; 2005 Oct; 30(10):1870-82. PubMed ID: 15785779
[TBL] [Abstract][Full Text] [Related]
28. Reduced efficacy of fluoxetine following MDMA ("Ecstasy")-induced serotonin loss in rats.
Durkin S; Prendergast A; Harkin A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1894-901. PubMed ID: 18824064
[TBL] [Abstract][Full Text] [Related]
29. Persistent cerebrovascular effects of MDMA and acute responses to the drug.
Ferrington L; Kirilly E; McBean DE; Olverman HJ; Bagdy G; Kelly PA
Eur J Neurosci; 2006 Jul; 24(2):509-19. PubMed ID: 16836637
[TBL] [Abstract][Full Text] [Related]
30. Behavioral and neurochemical profile of m-CPP following exposure to single restraint stress in rat.
Samad N; Haleem DJ
Acta Neurol Belg; 2009 Mar; 109(1):24-31. PubMed ID: 19402569
[TBL] [Abstract][Full Text] [Related]
31. Serotonin1B receptor activation mimics behavioral effects of presynaptic serotonin release.
Rempel NL; Callaway CW; Geyer MA
Neuropsychopharmacology; 1993 May; 8(3):201-11. PubMed ID: 8099482
[TBL] [Abstract][Full Text] [Related]
32. Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat.
Morley KC; Arnold JC; McGregor IS
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):648-57. PubMed ID: 15908091
[TBL] [Abstract][Full Text] [Related]
33. Implication of the 5-HT2A and 5-HT2C (but not 5HT1A) receptors located within the periaqueductal gray in the elevated plus-maze test-retest paradigm in mice.
Gomes KS; Nunes-De-Souza RL
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1261-9. PubMed ID: 19625008
[TBL] [Abstract][Full Text] [Related]
34. The effect of the repeated administration of the compound 3,4-methylenedioxymethamphetamine on the response of rats to the 5-HT2A,C receptor agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI).
Granoff MI; Ashby CR
Neuropsychobiology; 1998; 37(1):36-40. PubMed ID: 9438270
[TBL] [Abstract][Full Text] [Related]
35. Influences of the corticotropic axis and sympathetic activity on neurochemical consequences of 3,4-methylenedioxymethamphetamine (MDMA) administration in Fischer 344 rats.
Fernandez F; Aguerre S; Mormède P; Chaouloff F
Eur J Neurosci; 2002 Aug; 16(4):607-18. PubMed ID: 12270036
[TBL] [Abstract][Full Text] [Related]
36. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users.
McCann UD; Eligulashvili V; Mertl M; Murphy DL; Ricaurte GA
Psychopharmacology (Berl); 1999 Nov; 147(1):56-65. PubMed ID: 10591869
[TBL] [Abstract][Full Text] [Related]
37. MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat.
Clemens KJ; Van Nieuwenhuyzen PS; Li KM; Cornish JL; Hunt GE; McGregor IS
Psychopharmacology (Berl); 2004 May; 173(3-4):318-25. PubMed ID: 15029472
[TBL] [Abstract][Full Text] [Related]
38. Acute and long-term consequences of single MDMA administration in relation to individual anxiety levels in the rat.
Ho YJ; Pawlak CR; Guo L; Schwarting RK
Behav Brain Res; 2004 Mar; 149(2):135-44. PubMed ID: 15129777
[TBL] [Abstract][Full Text] [Related]
39. Developmental effects of +/-3,4-methylenedioxymethamphetamine on spatial versus path integration learning: effects of dose distribution.
Vorhees CV; Schaefer TL; Williams MT
Synapse; 2007 Jul; 61(7):488-99. PubMed ID: 17415794
[TBL] [Abstract][Full Text] [Related]
40. Activation of 5-HT3 receptors leads to altered responses 6 months after MDMA treatment.
Gyongyosi N; Balogh B; Katai Z; Molnar E; Laufer R; Tekes K; Bagdy G
J Neural Transm (Vienna); 2010 Mar; 117(3):285-92. PubMed ID: 20052506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
